Frontotemporal dementia with motor neuron disease
MONDO:0017161Frontotemporal dementia with motor neuron disease (FTD-MND) is a type of frontotemporal lobar degeneration characterized by the insidious onset (between the ages of 38-78 years) of dementia-associated psychiatric symptoms (e.g. personality changes, uninhibited behavior, irritability, aggressiveness), memory difficulties, global intellectual impairment, emotional disorders and transcortical motor aphasia that eventually leads to mutism, in addition to the manifestations of motor neuron disease such as neurogenic muscular wasting (similar to what is seen in amyotrophic lateral sclerosis). The disease is progressive, with death occurring 2-5 years after onset.
Also known as: FTD-ALS, FTD-MND, FTDALS, frontotemporal dementia with ALS, frontotemporal dementia with amyotrophic lateral sclerosis
31 clinical trials for this condition and its sub-types, 14 tagged with Frontotemporal dementia with motor neuron disease itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Frontotemporal dementia with motor neuron disease
-
Can a common alcoholism drug help slow ALS? new trial begins
Disease control OngoingThis early-stage study tests the safety of acamprosate, a drug used for alcohol dependence, in 30 adults with ALS who have a specific mutation in the C9orf72 gene. Participants take the pill three times daily for 24 weeks and undergo regular checkups, breathing tests, and spinal …
Phase 1 • Sponsor: National Institute of Neurological Disorders and Stroke (NINDS) • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Could a single gene injection slow frontotemporal dementia?
Disease control OngoingThis early-stage trial tests a gene therapy called PBFT02 for frontotemporal dementia (FTD) in people with specific genetic mutations. The therapy delivers a working copy of the GRN gene directly into the brain. The study involves 30 adults and primarily checks for safety and sid…
Phase 1/2 • Sponsor: Passage Bio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Simple blood draws could spot dementia years early
Knowledge-focused OngoingThis study tracks a protein called neurofilament light chain in the blood of 342 people who carry genetic mutations linked to frontotemporal dementia (FTD). Participants provide blood samples every three months for three years, often from home. The goal is to see if this biomarke…
Sponsor: The Bluefield Project to Cure Frontotemporal Dementia • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Groundbreaking study aims to speed up ALS treatment development
Knowledge-focused OngoingThis study enrolls people with ALS and related disorders, as well as healthy volunteers, to track biological markers (biomarkers) in urine, blood, and spinal fluid. The goal is to better understand how these markers change over time, which could help design more effective future …
Sponsor: University of Miami • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC